Marine bromophenols suppressed choroidal neovascularization by targeting HUWE1 through NF-κb signaling pathway

Kepeng Ou1, Youjian Li1, Yuwei Wang2

  • 1College of Pharmacy, National & Local Joint Engineering Research Center of Targeted and Innovative Therapeutics, IATTI, Chongqing University of Arts and Sciences, Chongqing, China.

Insights

Marine bromophenols (BDB) reduce inflammation and suppress choroidal neovascularization by targeting HUWE1 via the NF-κB pathway. This suggests BDB as a potential therapy for chronic eye inflammation.

Area of Science:

  • Ophthalmology
  • Molecular Biology
  • Pharmacology

Background:

  • Chronic inflammation in the retina and choroid drives choroidal neovascularization (CNV) recurrence.
  • Anti-VEGF treatments require regular injections due to persistent inflammation.
  • Marine bromophenols (BDB) exhibit anti-inflammatory properties, but their mechanism is unclear.

Purpose of the Study:

  • To investigate the mechanism by which BDB suppresses endothelial cell function and choroidal neovascularization.
  • To identify the molecular targets of BDB in the context of inflammation.

Main Methods:

  • In vitro and in vivo studies using endothelial cells and choroidal explants.
  • Analysis of inflammatory cytokine levels (IL-1β, IL-6, TNF-α, IL-4, MMP-9).
  • Investigation of the NF-κB pathway and protein-protein interactions using Co-IP assay to identify BDB targets.

Main Results:

  • BDB restricted endothelial cell function and suppressed choroidal explants without affecting cell viability.
  • BDB significantly reduced inflammatory cytokines and NF-κB p65 phosphorylation.
  • HUWE1 was identified as a binding partner of BDB, and its overexpression enhanced BDB's suppressive effects.

Conclusions:

  • BDB suppresses endothelial cell function and choroidal neovascularization by targeting HUWE1 through the NF-κB pathway.
  • BDB shows potential as a therapeutic candidate for treating chronic inflammation in conditions like CNV.